What are the latest advances in Pseudomyxoma Peritonei?

Pseudomyxoma peritonei (PMP) research is currently focused on optimizing Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and investigating targeted molecular therapies. While progress is incremental, recent clinical studies are exploring the use of novel systemic agents and improved biomarker identification to better predict treatment response in patients with this rare condition.

What are the most promising research directions for Pseudomyxoma peritonei?

The primary research focus for Pseudomyxoma peritonei remains the standardization of the CRS/HIPEC procedure to improve long-term survival outcomes. Because Pseudomyxoma peritonei is often associated with mutations in the GNAS and KRAS genes, researchers are investigating whether these genetic markers can guide personalized treatment plans. Additionally, there is growing interest in using immunotherapy for patients whose tumors demonstrate high mutational burdens, though this remains in early-stage exploration.

What new diagnostic tools are being developed for Pseudomyxoma peritonei?

Improving early detection is a priority, as Pseudomyxoma peritonei is frequently discovered incidentally during other abdominal surgeries. Current research is evaluating the following diagnostic and monitoring tools:

• Liquid Biopsies: Studying circulating tumor DNA (ctDNA) to monitor disease recurrence after surgery.


• Advanced Imaging: Utilizing PET/CT scans with specialized tracers to better map tumor distribution before intervention.


• Serum Biomarkers: Standardizing the use of CEA, CA19-9, and CA-125 levels to track disease progression in the 110 members of the DiseaseMaps.org community and beyond.

How are clinical trials advancing care for Pseudomyxoma peritonei?

Clinical trials for Pseudomyxoma peritonei are increasingly looking at "neoadjuvant" (pre-surgical) chemotherapy to shrink tumors before CRS/HIPEC. While there is no single "breakthrough" cure, the international medical community is collaborating through groups like the Peritoneal Surface Oncology Group International (PSOGI) to create global registries. Patients can find active studies on ClinicalTrials.gov by searching for "peritoneal carcinomatosis" or "appendiceal cancer," which are the most common origins of Pseudomyxoma peritonei.

Next steps

• Consult with a surgical oncologist who specializes specifically in peritoneal surface malignancies.


• Register with the DiseaseMaps.org community to connect with other patients managing Pseudomyxoma peritonei.


• Monitor ClinicalTrials.gov regularly, filtering by your location and the specific pathology of your tumor.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your specialist physician regarding your specific treatment plan.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pseudomyxoma peritonei


• Orphanet: Pseudomyxoma peritonei (ORPHA:732)


• Peritoneal Surface Oncology Group International (PSOGI)


• ClinicalTrials.gov (U.S. National Library of Medicine)